{
  "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed",
  "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 52,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "timeline",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "The slide uses a timeline framework to highlight key clinical trial milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/10",
  "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed",
  "deckJsonHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed.json",
  "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "OC = ovarian cancer; NSCLC = non-small cell lung cancer; CTx = chemotherapy; EGFRm = epidermal growth factor receptor-mutant; EC = endometrial cancer; FLOT = fluorouracil, leucovorin, oxaliplatin and docetaxel; GEJ = gastroesophageal junction cancer; ECOG PS = Eastern Cooperative Oncology Group performance status; PD-L1 = programmed cell death ligand 1; TAP = tumour area positivity; Q4W = every four weeks; EFS = event-free survival; ITT = intent-to-treat; pCR = pathologic complete response.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59634427-5518-48a1-9fc7-6f79dee208ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.82,
        "x": 0.09,
        "y": 0.33
      },
      "kind": "framework",
      "text": null,
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1f6b693-ae9d-4b9c-a8f5-512997e59bcc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.84
      },
      "kind": "metric",
      "text": "7 positive key oncology data read-outs to date in 2023",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4671c3c-64d7-4f4f-98e2-114ccf8a12a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Pipeline news flow continues with early efficacy signal in Phase III MATTERHORN trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd7807d5-3889-44e6-9be1-fca86dd0c58a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "AstraZeneca oncology momentum in 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2d275c4-905d-4d6c-941f-2bb74b6c1167",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "c9e90655-e1a5-4e78-a935-8f578fd23b0d",
      "evidence": "Sequential presentation of clinical trial milestones along a horizontal axis.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 8,
      "beatId": "825356c1-11c2-4d2a-9dc4-e3ccfd780129",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The deck highlights the company's diverse portfolio and pipeline, emphasizing the potential for combinations",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5bb0992b-1a81-4416-bc2d-f98f5d61437b",
      "evidence": "The deck highlights the company's diverse portfolio and pipeline, implying that innovation is crucial",
      "position": 0,
      "objective": "What if AstraZeneca doesn't innovate in oncology?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}